Since the introduction of widespread prostate-specific antigen (PSA) screening in the early 1990s, diagnosis and radical treatment of prostate cancer (PCa) has led to a 50% reduction in PCa-specific mortality since peak rates.
1 While PSA screening was once widely accepted and ubiquitous, opinions on the utility of screening have shifted in recent years, and there is now controversy surrounding its use as a screening tool because of the overdiagnosis and overtreatment of indolent cancers.
2 The concern over the utility of PSA as a screening tool was highlighted by the United States Preventive Services Task Force recommendation against PSA screening in 2012,
3 although recently the task force has revised its statement to promote shared decision-making between patients and physicians.
4 This position has factored in the increased use of active surveillance for men with low-risk PCa, as defined by the American Urological Association.
5,6